Latest other assets for ATTBF: $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Abattis Bioceuticals's other assets stands at $0 as of September 2019. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Abattis Bioceuticals reported $0 in other assets versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
In the prior-year period, the figure was $0. Sustained growth in other assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Abattis Bioceuticals's other assets evolved across reporting periods, while the comparison chart places ATTBF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, other assets is commonly used to spot outliers. Abattis Bioceuticals's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.